Semorinemab (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code names MTAU-9937A, RG-6100, RO-7105705) is a monoclonal antibody against tau which was under development for the treatment of Alzheimer's disease but was discontinued.
[1][2][3] It binds to the N-terminus of all six isoforms of tau.
[2][3] The drug was ineffective in the treatment of Alzheimer's disease in two phase 2 clinical trials.
[2][3] Clinical development of semorinemab for Alzheimer's disease was discontinued in February 2024.
[1]